INVESTIGATION ALERT: The Schall Law Firm Announces It is
Investigating Claims against Global Blood Therapeutics, Inc. and
Encourages Investors with Losses in Excess of $100,000 to Contact the
Firm

September 14, 2018 06:07 PM Eastern Daylight Time

LOS ANGELES--(BUSINESS WIRE)--The
Schall Law Firm, a national shareholder rights litigation firm,
announces that it is investigating claims on behalf of investors of
Global Blood Therapeutics, Inc. (“Global Blood” or “the Company”)
(NASDAQ: GBT)
for violations of §§10(b) and 20(a) of the Securities Exchange Act of
1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and
Exchange Commission.

The investigation focuses on whether the Company issued false and/or
misleading statements and/or failed to disclose information pertinent to
investors. Stat published an article about Global Blood, claiming
that there are “important risks that investors might be glossing over”
about the likelihood of Global Blood’s new drug for sickle cell disease,
voxelotor, being approved by the FDA. The article refers to recent
results of a Phase 3 clinical trial, stating “Global Blood lacks data
demonstrating voxelotor reduces the frequency of crises,” a typically
necessary requirement for FDA approval for sickle cell disease. The
article also asserted, “[i]n the Phase 3 study, voxelotor did not
improve the quality of life of sickle cell patients.” Based on this
article, Global Blood’s share price fell more than 7% on the same day.

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of
the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA
90067, at 424-303-1964, to discuss your rights free of charge. You can
also reach us through the firm's website at www.schallfirm.com,
or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until
certification occurs, you are not represented by an attorney. If you
choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and
specializes in securities class action lawsuits and shareholder rights
litigation.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and rules of ethics.